Control of bleeding during and after prostatectomy.
D000614:Aminocaproates / Q000009:adverse effects / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007611:Aprotinin / Q000009:adverse effects / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D007902:Length of Stay; D008297:Male; D009203:Myocardial Infarction / Q000150:complications; D011183:Postoperative Complications / Q000517:prevention & control*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000517:prevention & control*
D000614:Aminocaproates; D000933:Antifibrinolytic Agents; D003509:Cyclohexanecarboxylic Acids; D007611:Aprotinin